Tarsus Pharmaceuticals TARS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$2.99M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 34.4% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 13.67% to 12.96% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +2,600,351 | 6.6% |
| abrdn plc | Mutual Fund | 2026/Q3 | +505,591 | 1.0% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +398,450 | 1.1% |
| Barclays PLC | Public Company | 2026/Q3 | +226,653 | 0.5% |
| Wasatch Advisors LP | Mutual Fund | 2026/Q3 | +99,473 | 0.9% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +95,285 | 0.5% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +85,945 | 3.8% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +862,545 | 2.9% |
| Vestal Point Capital, LP | Hedge Fund | 2026/Q3 | +850,000 | 2.1% |
| Janus Henderson Group plc | Mutual Fund | 2026/Q3 | +567,833 | 5.7% |
| MFS Investment Management | Mutual Fund | 2026/Q3 | +427,008 | 1.0% |
| Tang Capital Management, LLC | Mutual Fund | 2026/Q3 | +379,642 | 3.2% |
| Wasatch Advisors LP | Mutual Fund | 2026/Q3 | +368,568 | 0.8% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +356,153 | 1.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +303,525 | 8.8% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 2 Nov 2026 | Neera Clase | Chief Commercial Officer | Other Derivative Acquisition | +6,678 | – | 6,678 |
| 2 Nov 2026 | Neera Clase | Chief Commercial Officer | Other Derivative Acquisition | +10,587 | $72.64 | 10,587 |
| 31 Oct 2026 | Neera Clase | Chief Commercial Officer | Initial Statement of Beneficial | +0 | – | 76,862 |
| 14 Sep 2026 | William Link | Independent Director | Automatic Disposition | -12,299 | $80.01 | 94,487 |
| 14 Sep 2026 | William Link | Independent Director | Derivative Exercise and Sale | -201 | $78.33 | 94,487 |
| 14 Sep 2026 | David E. Pyott | Independent Director | Derivative Exercise and Retained | +201 | – | 9,575 |
| 14 Sep 2026 | Wendy Yarno | Lead Independent Director | Derivative Exercise and Retained | +302 | – | 16,956 |
| 3 Sep 2026 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $91.27 | 861,412 |
| 3 Sep 2026 | Seshadri Neervannan | Chief Operating Officer | Open Market Disposition | -4,564 | $85.00 | 79,007 |
| 3 Sep 2026 | Elizabeth Yeu-Lin | Chief Medical Officer | Automatic Disposition | -13,953 | $90.00 | 16,177 |
| 1 Sep 2026 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $80.06 | 871,412 |
| 1 Sep 2026 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -8,000 | $81.80 | – |
| 1 Sep 2026 | Elizabeth Yeu-Lin | Chief Medical Officer | Intent to Sell (Form 144) | -5,387 | $80.00 | – |
| 1 Sep 2026 | Elizabeth Yeu-Lin | Chief Medical Officer | Intent to Sell (Form 144) | -1,590 | $80.00 | – |
| 1 Sep 2026 | Elizabeth Yeu-Lin | Chief Medical Officer | Automatic Disposition | -11,578 | $80.00 | 30,130 |
| 31 Aug 2026 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -77,698 | $73.96 | – |
| 31 Aug 2026 | Elizabeth Yeu-Lin | Chief Medical Officer | Intent to Sell (Form 144) | -4,601 | $73.86 | – |
| 24 Aug 2026 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -81,332 | $71.85 | – |
| 18 Aug 2026 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -53,043 | $72.00 | – |
| 24 Jun 2026 | William Link | Independent Director | Other Derivative Acquisition | +3,223 | – | 806 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 6,066,524 | 13.0% | 6.9 |
| 15 Oct 2026 | 5,731,409 | 12.2% | 5.7 |
| 30 Sep 2026 | 6,070,928 | 13.0% | 8.3 |
| 15 Sep 2026 | 6,127,884 | 13.1% | 6.6 |
| 31 Aug 2026 | 6,011,550 | 13.7% | 9.8 |
| 14 Aug 2026 | 5,997,475 | 13.7% | 7.5 |
No comments yet — be the first to weigh in on TARS.
Sign in to join the discussion.